Allotment of 6,25,000 Equity Shares and 29,50,000 Warrants on preferential basis under SEBI (ICDR) Regulations, 2018 through Circulation on Tuesday, 24th February, 2026

Qip At PremiumFund Raising View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.0%Reaction day

₹51.40

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+3.8% vs market

Specialty Chemicals peers, median of 86sector-0.2%+4.2% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 4.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.0+0.2+3.8-0.2+4.2

Next day

+1.2+0.4+0.7-0.4+1.5

+0.2-0.6+0.9-1.0+1.2

-2.7-2.8+0.1-3.5+0.8

-2.7-5.4+2.7-5.3+2.6

+1.1-4.4+5.5-4.2+5.3

-4.7-7.1+2.4-6.9+2.2

15d

+2.5-7.8+10.4-7.1+9.7

+1.1-6.6+7.7-7.3+8.4

-1.3+7.7-9.0+3.7-4.9

-4.5+10.3-14.7+6.5-11.0

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eiko Lifesciences has allotted 6,25,000 equity shares at Rs. 55 each (face value Rs. 10, premium of Rs. 45), raising about Rs. 3.44 crore. It has also allotted 29,50,000 convertible warrants at the same Rs. 55 price, which on full conversion would bring in another Rs. 16.22 crore, with 25% (Rs. 4.06 crore) received upfront. Most allottees are from the promoter and promoter group — Bhavesh Dhirajlal Tanna (promoter) and Lenus Finvest Pvt Ltd (promoter group) — along with three non-promoter allottees including V Square Pharmachem Pvt Ltd. The shares will rank equally with existing equity shares. BSE has already given in-principle approval for the issue.

Likely market impact

The preferential issue is promoter-led, signalling insider confidence, but full conversion of warrants would meaningfully expand the share count and dilute existing shareholders. The Rs. 55 pricing at a premium to face value suggests the company raised funds without distress pricing.